Elben Guimaraes

2 months ago | cellandgene.com | Elben Guimaraes |Xiaojun Liu |Junwei Sun |Lucia Fernandez |Lucia Fernández

Each approach has its advantages and drawbacks. This guide should help you decide which one, or perhaps a hybrid strategy, is best for your company. Exploring Strategies For Developing Robust AAV PlatformsExplore advanced AAV production platforms that enhance efficiency, scalability, and compliance, paving the way for safe and accessible gene therapies.

Oct 21, 2024 | cellandgene.com | Elben Guimaraes |Robert Ossig |Junwei Sun |Lucia Fernandez |Lucia Fernández

On-Demand Webinar - The Road to Approval: Viral Clearance Strategies for Non-Enveloped Viral VectorsDid you know that the ICH Q5A(R2) guideline is now including the expectation for viral clearance studies for non-enveloped viral vectors? Watch this webinar to get the keys to design a successful study for your AAV products. Each approach has its advantages and drawbacks, making the decision-making process crucial for your organization.

Oct 7, 2024 | bioprocessonline.com | Elben Guimaraes

By Elben Guimaraes, upstream manufacturing expert As gene and cell therapies rapidly advance, biotechnology companies face the critical challenge of determining the most effective manufacturing strategy. These therapies can potentially cure patients and transform their lives, but they require precise and complex manufacturing processes.

Oct 7, 2024 | cellandgene.com | Elben Guimaraes

By Elben Guimaraes, upstream manufacturing expert As gene and cell therapies rapidly advance, biotechnology companies face the critical challenge of determining the most effective manufacturing strategy. These therapies can potentially cure patients and transform their lives, but they require precise and complex manufacturing processes.